Gilead Sciences has acquired Interius BioTherapeutics for $350 million, gaining exclusive rights to an innovative technology enabling genetic modification of immune cells inside the body. This approach, termed 'in vivo' cell therapy, represents a strategic move to broaden access to CAR-T therapies, which traditionally involve complex ex vivo manufacturing processes. The acquisition aligns with Gilead's efforts to develop simpler, scalable immune therapies, potentially impacting treatment paradigms in oncology.